Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 6
2005 18
2006 27
2007 82
2008 101
2009 94
2010 131
2011 105
2012 126
2013 137
2014 201
2015 157
2016 129
2017 143
2018 156
2019 123
2020 193
2021 170
2022 101
2023 74
2024 39

Text availability

Article attribute

Article type

Publication date

Search Results

2,066 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for darunavir ethanolate
Search for darunavir-etanolate instead (1 results)
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.
Chavda VP, Gajjar N, Shah N, Dave DJ. Chavda VP, et al. Eur J Med Chem Rep. 2021 Dec;3:100013. doi: 10.1016/j.ejmcr.2021.100013. Epub 2021 Oct 22. Eur J Med Chem Rep. 2021. PMID: 36575695 Free PMC article. Review.
The current manuscript aims to evaluate the repurposing of an anti-HIV drug Darunavir Ethanolate in COVID-19 treatment with in silico study and we discuss the therapeutic progress of Darunavir Etanolate, to prevent SARS-CoV-2 replication, which supports its c …
The current manuscript aims to evaluate the repurposing of an anti-HIV drug Darunavir Ethanolate in COVID-19 treatment with in …
Darunavir: A comprehensive profile.
Darwish IA, Al-Majed AA, Alsaif NA, Bakheit AH, Herqash RN, Alzaid A. Darwish IA, et al. Profiles Drug Subst Excip Relat Methodol. 2021;46:1-50. doi: 10.1016/bs.podrm.2020.07.001. Epub 2020 Aug 21. Profiles Drug Subst Excip Relat Methodol. 2021. PMID: 33461696 Review.
Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. ...Darunavir is unique among currently available protease inhibitors b …
Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-bu …
Investigating the Physicochemical Stability of Highly Purified Darunavir Ethanolate Extracted from PREZISTA Tablets.
Nie H, Mo H, Byrn SR. Nie H, et al. AAPS PharmSciTech. 2018 Jul;19(5):2407-2417. doi: 10.1208/s12249-018-1036-x. Epub 2018 Jun 4. AAPS PharmSciTech. 2018. PMID: 29869313
Understanding physicochemical stability of darunavir ethanolate is expected to be of critical importance for the development and manufacturing of high-quality darunavir-related pharmaceutical products. ...Amorphization was observed under thermal storage cause …
Understanding physicochemical stability of darunavir ethanolate is expected to be of critical importance for the development a …
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Deeks ED. Deeks ED. Drugs. 2018 Jul;78(10):1013-1024. doi: 10.1007/s40265-018-0934-2. Drugs. 2018. PMID: 29915897 Review.
Darunavir/cobicistat/emtricitabine/tenofovir AF (Symtuza()) is the first protease inhibitor (PI)-based single-tablet regimen (STR) available for the treatment of adults and adolescents (aged 12 years) with HIV-1 infection. ...Over 48 weeks in phase 3 trials, darunavir …
Darunavir/cobicistat/emtricitabine/tenofovir AF (Symtuza()) is the first protease inhibitor (PI)-based single-tablet regimen (STR) av …
Darunavir for use in pregnant women with HIV.
Pope R Jr, Kashuba A. Pope R Jr, et al. Expert Rev Clin Pharmacol. 2017 Dec;10(12):1317-1327. doi: 10.1080/17512433.2017.1390428. Epub 2017 Nov 14. Expert Rev Clin Pharmacol. 2017. PMID: 28988509 Review.
Areas covered: This is a brief review of the use of protease inhibitor therapy during pregnancy, and a discussion of darunavir's utility in this area. Clinical pharmacology and trial data are reviewed, and the safety, efficacy and dosing of darunavir during pregnanc …
Areas covered: This is a brief review of the use of protease inhibitor therapy during pregnancy, and a discussion of darunavir's util …
Darunavir for the treatment of HIV infection.
Spagnuolo V, Castagna A, Lazzarin A. Spagnuolo V, et al. Expert Opin Pharmacother. 2018 Jul;19(10):1149-1163. doi: 10.1080/14656566.2018.1484901. Epub 2018 Jun 18. Expert Opin Pharmacother. 2018. PMID: 29913082 Review.
Darunavir (DRV) was the last approved protease inhibitor (PI) and has been extensively used for the treatment of HIV in both naive and experienced subjects due to its high genetic barrier and efficacy. ...
Darunavir (DRV) was the last approved protease inhibitor (PI) and has been extensively used for the treatment of HIV in both naive an …
Darunavir/cobicistat once daily for the treatment of HIV.
Kakuda TN, Crauwels H, Opsomer M, Tomaka F, van de Casteele T, Vanveggel S, Iterbeke K, de Smedt G. Kakuda TN, et al. Expert Rev Anti Infect Ther. 2015 Jun;13(6):691-704. doi: 10.1586/14787210.2015.1033400. Expert Rev Anti Infect Ther. 2015. PMID: 25962100 Review.
A current focus in HIV management is improving adherence by minimizing pill burden with convenient formulations, including fixed-dose combinations (FDCs). Darunavir, a HIV protease inhibitor, co-administered with low-dose ritonavir (800/100 mg once daily), is recommended i …
A current focus in HIV management is improving adherence by minimizing pill burden with convenient formulations, including fixed-dose combin …
Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women.
Khoo S, Peytavin G, Burger D, Hill A, Brown K, Moecklinghoff C, La Porte C, Hadacek MB. Khoo S, et al. AIDS Rev. 2017 Jan-Mar;19(1):16-23. AIDS Rev. 2017. PMID: 28182610 Review.
The dosage of darunavir/ritonavir is 800/100 mg once daily for treatment-naive patients or treatment-experienced patients with no prior darunavir resistance associated mutations, and 600/100 mg twice daily for treatment-experienced patients with one or more darun …
The dosage of darunavir/ritonavir is 800/100 mg once daily for treatment-naive patients or treatment-experienced patients with no pri …
Rezolsta (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.
Curran A, Pérez-Valero I, Moltó J. Curran A, et al. AIDS Rev. 2015 Apr-Jun;17(2):114-20. AIDS Rev. 2015. PMID: 26035169 Review.
The convenience of this combination makes boosted darunavir easier to take, thus improving adherence. Exposure to darunavir is equivalent when it is administered with cobicistat or with ritonavir. Darunavir/cobicistat-based antiretroviral therapy has shown co …
The convenience of this combination makes boosted darunavir easier to take, thus improving adherence. Exposure to darunavir is …
2,066 results